

### Amendments to the Claims

1. -18. (Cancelled)

19. (Currently Amended) A method for inducing apoptosis in imatinib mesylate refractory cancer cells, the method comprising the steps of contacting the living cells with a ~~tyrosine kinase inhibitor~~ imatinib mesylate and suberoylanilide hydroxamic acid, ~~a histone deacetylase inhibitor~~.

20. (Previously Presented) The method of claim 19 wherein the tyrosine kinase inhibitor is imatinib mesylate.

21. (Canceled)

22. (Canceled)

23. (Currently Amended) Method of claim 19 wherein the living cells are exposed to the tyrosine kinase inhibitor and the histone deacetylase inhibitor for about 48 hours.

24. (Currently Amended) Method of claim 19 wherein the cancer cells are chronic myelogenous leukemia cells.

25. (Canceled)

26. (New) The method of claim 24 wherein the chronic myelogenous leukemia cells are selected from the group consisting of accelerated-phase chronic myelogenous leukemia cells and blast crisis phase myelogenous leukemia cells.